Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Adial Pharmaceuticals stock

ADIL
US00688A1060
A2N38J

Price

0.97
Today +/-
-0.02
Today %
-2.60 %
P

Adial Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Adial Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Adial Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Adial Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Adial Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Adial Pharmaceuticals Stock Price History

DateAdial Pharmaceuticals Price
10/1/20240.97 undefined
9/30/20241.00 undefined
9/27/20241.01 undefined
9/26/20241.00 undefined
9/25/20241.04 undefined
9/24/20241.05 undefined
9/23/20241.06 undefined
9/20/20241.05 undefined
9/19/20241.05 undefined
9/18/20241.08 undefined
9/17/20241.10 undefined
9/16/20241.09 undefined
9/13/20241.08 undefined
9/12/20241.09 undefined
9/11/20241.10 undefined
9/10/20241.01 undefined
9/9/20241.01 undefined
9/6/20241.00 undefined
9/5/20241.02 undefined
9/4/20241.04 undefined
9/3/20241.00 undefined

Adial Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Adial Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adial Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adial Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Adial Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Adial Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Adial Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adial Pharmaceuticals’s growth potential.

Adial Pharmaceuticals Revenue, EBIT and net profit per share

DateAdial Pharmaceuticals RevenueAdial Pharmaceuticals EBITAdial Pharmaceuticals Net Income
2029e45.43 M undefined0 undefined739,088.3 undefined
2028e22.22 M undefined-4.29 M undefined-146,596.03 undefined
2027e0 undefined-23.65 M undefined-1.05 M undefined
2026e0 undefined-18.17 M undefined-1.53 M undefined
2025e0 undefined-10.34 M undefined-1.42 M undefined
2024e0 undefined-7.36 M undefined-3.53 M undefined
20230 undefined-6.89 M undefined-5.12 M undefined
20220 undefined-13.32 M undefined-12.73 M undefined
20210 undefined-17.74 M undefined-19.42 M undefined
20200 undefined-10.93 M undefined-10.89 M undefined
20190 undefined-8.24 M undefined-8.59 M undefined
20180 undefined-6.99 M undefined-11.63 M undefined
20170 undefined-1 M undefined-1.14 M undefined
20160 undefined-410,000 undefined-420,000 undefined
20150 undefined-800,000 undefined-820,000 undefined

Adial Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000002245
--------------104.55
---------------
000000000000000
00-1-6-8-10-17-13-6-7-10-18-23-40
--------------18.18-
00-1-11-8-10-19-12-5-3-1-1-100
---1,000.00-27.2725.0090.00-36.84-58.33-40.00-66.67----
0.260.260.260.190.390.50.7411.42000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Adial Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Adial Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (k)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
0.160.090.023.876.784.46.0642.83
000000000
000000000
000000000
402010820900730400780371.6
0.20.110.034.697.685.136.464.783.2
0000003002400
000000001.53
00000350000
1010101010104604603.91
0000002502500
000000000
0.010.010.010.010.010.361.010.951.54
0.210.120.044.77.695.497.475.734.74
                 
00010101020301.66
9.689.83-0.616.4727.7635.4954.4366.9272.88
-9.52-9.94-0.4-12.04-20.63-31.52-50.94-63.67-68.8
000000000
000000000
0.16-0.11-14.447.143.983.513.284.08
4020340260190650290390127.39
00000.350.862.431.390.53
00000010100
20230690000000
000000000
0.060.251.030.260.541.512.731.790.65
000000000
00000020200
0000001.220.640
0000001.240.660
0.060.251.030.260.541.513.972.450.65
0.220.140.034.77.685.497.485.734.74
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Adial Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Adial Pharmaceuticals's financial health and stability.

Assets

Adial Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Adial Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Adial Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Adial Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20152016201720182019202020212022
00-1-11-8-10-19-12
00000000
00000000
000001,0001,000-1,000
00092262
00000000
00000000
000-2-6-7-11-11
00000000
00000000
00000000
00000000
00000000
000695139
000695139
--------
00000000
00032-21-2
-0.47-0.27-0.49-2.5-6.34-7.63-12.01-11.19
00000000

Adial Pharmaceuticals stock margins

The Adial Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adial Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adial Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Adial Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Adial Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Adial Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Adial Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adial Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adial Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adial Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Adial Pharmaceuticals Margin History

Adial Pharmaceuticals Gross marginAdial Pharmaceuticals Profit marginAdial Pharmaceuticals EBIT marginAdial Pharmaceuticals Profit margin
2029e0 %0 %1.63 %
2028e0 %-19.31 %-0.66 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

Adial Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Adial Pharmaceuticals earnings per share therefore indicates how much revenue Adial Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Adial Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Adial Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Adial Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adial Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Adial Pharmaceuticals Revenue, EBIT and net profit per share

DateAdial Pharmaceuticals Sales per ShareAdial Pharmaceuticals EBIT per shareAdial Pharmaceuticals Earnings per Share
2029e37.94 undefined0 undefined0.62 undefined
2028e18.55 undefined0 undefined-0.12 undefined
2027e0 undefined0 undefined-0.88 undefined
2026e0 undefined0 undefined-1.28 undefined
2025e0 undefined0 undefined-1.18 undefined
2024e0 undefined0 undefined-2.95 undefined
20230 undefined-4.83 undefined-3.6 undefined
20220 undefined-13.32 undefined-12.73 undefined
20210 undefined-23.97 undefined-26.24 undefined
20200 undefined-21.86 undefined-21.78 undefined
20190 undefined-21.13 undefined-22.03 undefined
20180 undefined-36.79 undefined-61.21 undefined
20170 undefined-3.85 undefined-4.38 undefined
20160 undefined-1.58 undefined-1.62 undefined
20150 undefined-3.08 undefined-3.15 undefined

Adial Pharmaceuticals business model

Adial Pharmaceuticals Inc was founded in 2010 in Charlottesville, Virginia. The company focuses on the discovery and development of drugs for the treatment of addiction disorders such as alcohol and nicotine dependence. Adial's business model is based on the belief that current therapies for addiction disorders are insufficient and that there is a need for more targeted and effective medications. The company develops drugs that target specific biological processes in the brain associated with addiction disorders. Adial has several divisions, including research and development, manufacturing, and clinical studies. The company has a promising pipeline of candidate molecules in various stages of development. The flagship product of Adial is AD04, which was developed for the treatment of alcohol dependence. AD04 is based on a novel approach called genetic prediction. It targets a specific biological process known as the opioid receptor and blocks it to reduce the craving for alcohol. Adial has recently completed a Phase 3 clinical trial with AD04, which has yielded promising results. The results suggest that AD04 is effective in reducing alcohol consumption in people with the genetic prediction. Adial plans to market AD04 in the USA and Europe. Adial also has a collaboration with the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the USA. This collaboration focuses on the development of drugs for the treatment of nicotine dependence. Adial has developed a promising molecule candidate that is currently being tested in Phase 2 clinical trials. Adial also has a division for manufacturing and technology partnerships. The company collaborates with various stakeholders in the pharmaceutical and biotech industry to develop technological solutions that can accelerate the development of new drugs. Overall, Adial Pharmaceuticals has focused on the discovery and development of drugs for the treatment of addiction disorders. The company has a promising pipeline of candidate molecules and has completed clinical trials with its flagship product AD04. Adial is also working in collaboration with renowned institutions such as NIDA of the NIH to expand the scope of its research and development. Adial Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Adial Pharmaceuticals SWOT Analysis

Strengths

1. Strong research and development capabilities, enabling the company to create innovative pharmaceutical products.

2. Established brand reputation in the pharmaceutical industry.

3. Robust financial position, allowing for investment in growth opportunities.

Weaknesses

1. Limited product portfolio, relying heavily on a single drug.

2. Vulnerability to regulatory changes and strict industry regulations.

3. Reliance on external partners for manufacturing and distribution.

Opportunities

1. Growing pharmaceutical market, particularly in the field of drug addiction treatment.

2. Increasing demand for personalized medicine and targeted therapies.

3. Potential for international expansion and market penetration.

Threats

1. Intense competition from other pharmaceutical companies.

2. Potential for legal and patent disputes.

3. Economic fluctuations impacting consumer purchasing power.

Adial Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Adial Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Adial Pharmaceuticals shares outstanding

The number of shares was Adial Pharmaceuticals in 2023 — This indicates how many shares 1.425 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Adial Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Adial Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Adial Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adial Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Adial Pharmaceuticals stock splits

In Adial Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Adial Pharmaceuticals.

Adial Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.55 -0.59  (-8.12 %)2024 Q2
3/31/2024-0.34 -0.62  (-84.19 %)2024 Q1
12/31/2023-0.78 -1.35  (-74.15 %)2023 Q4
9/30/2023-1.16 -1.18  (-1.93 %)2023 Q3
6/30/2023-1.53 0.96  (162.75 %)2023 Q2
3/31/2023-3.57 -2.75  (22.97 %)2023 Q1
12/31/2022-3.83 -2.75  (28.1 %)2022 Q4
9/30/2022-4.59 -3  (34.64 %)2022 Q3
6/30/2022-3.7 -4  (-8.18 %)2022 Q2
3/31/2022-4.34 -3.25  (25.03 %)2022 Q1
1
2

Adial Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
5.07640 % Claiborne (Cary J)60,79903/29/2024
4.25013 % Stilley (William B. III)50,903011/17/2023
4.01585 % Manchester Capital Management LLC48,097012/31/2023
13.27567 % Armistice Capital LLC159,000159,00012/31/2023
1.93708 % Renaissance Technologies LLC23,20023,20012/31/2023
1.23480 % Susquehanna International Group, LLP14,78914,78912/31/2023
1.13010 % Newman (James W. Jr.)13,53503/29/2024
0.88546 % Truluck (Joseph)10,60503/29/2024
0.88012 % En Fideicomiso De Mi Vida Trust10,54103/29/2024
0.87102 % Johnson (Bankole A)10,432-23/29/2024
1
2
3
4
5
...
6

Adial Pharmaceuticals Executives and Management Board

Mr. Cary Claiborne62
Adial Pharmaceuticals President, Chief Executive Officer, Director (since 2021)
Compensation 1.02 M
Mr. Joseph Truluck45
Adial Pharmaceuticals Chief Financial Officer, Treasurer, Secretary
Compensation 442,620
Dr. Bankole Johnson63
Adial Pharmaceuticals Chief Medical Officer (since 2010)
Compensation 375,000
Mr. Tony Goodman59
Adial Pharmaceuticals Chief Operating Officer, Director (since 2017)
Compensation 124,168
Mr. Kevin Schuyler54
Adial Pharmaceuticals Independent Chairman of the Board (since 2016)
Compensation 108,168
1
2

Most common questions regarding Adial Pharmaceuticals

What values and corporate philosophy does Adial Pharmaceuticals represent?

Adial Pharmaceuticals Inc represents a commitment to improving patient treatment outcomes by focusing on the development of innovative therapies. The company is dedicated to advancing precision medicine through personalized treatment options. Adial Pharmaceuticals Inc values research, collaboration, and patient-centric care, aiming to address unmet medical needs with its cutting-edge solutions. By leveraging advanced technologies and strategic partnerships, the company aims to create value for patients, healthcare providers, and shareholders. Adial Pharmaceuticals Inc's corporate philosophy revolves around the pursuit of scientific excellence, ethical practices, and delivering innovative solutions to improve the quality of life for individuals affected by various medical conditions.

In which countries and regions is Adial Pharmaceuticals primarily present?

Adial Pharmaceuticals Inc is primarily present in the United States of America.

What significant milestones has the company Adial Pharmaceuticals achieved?

Some significant milestones achieved by Adial Pharmaceuticals Inc include the successful completion of Phase 2b clinical trials for their lead product, AD04, which aims to treat alcohol use disorder. The company has also obtained Fast Track Designation from the U.S. FDA for AD04, recognizing the urgent need for effective treatments in this area. Adial Pharmaceuticals has strengthened its intellectual property portfolio with the issuance of multiple patents and has secured collaborations with leading research institutions to further develop their innovative therapeutic solutions. These milestones highlight the company's progress in advancing its novel drug candidates and signify promising prospects for Adial Pharmaceuticals Inc.

What is the history and background of the company Adial Pharmaceuticals?

Adial Pharmaceuticals Inc is a biopharmaceutical company based in Virginia, USA. It was founded in 2010 and is focused on developing innovative treatments for addiction and related disorders. Adial Pharmaceuticals aims to revolutionize the way addiction is treated by providing personalized medications and therapeutic interventions. The company's flagship product, AD04, is being developed as a potential treatment for Alcohol Use Disorder (AUD). Adial Pharmaceuticals is committed to improving the lives of individuals affected by addiction and aims to address the growing need for effective and accessible treatment options. With its dedicated team and visionary approach, Adial Pharmaceuticals continues to make significant strides in the field of addiction therapeutics.

Who are the main competitors of Adial Pharmaceuticals in the market?

Some of the main competitors of Adial Pharmaceuticals Inc in the market include Alkermes plc, BioMarin Pharmaceutical Inc, and Catabasis Pharmaceuticals Inc.

In which industries is Adial Pharmaceuticals primarily active?

Adial Pharmaceuticals Inc primarily operates in the pharmaceutical industry.

What is the business model of Adial Pharmaceuticals?

Adial Pharmaceuticals Inc. operates with the business model of developing and commercializing innovative biopharmaceutical drugs. The company primarily focuses on the development of treatments for alcohol use disorder (AUD) and other addiction-related disorders. Adial's proprietary technology, known as AD04, is a selective serotonin-3 antagonist, which is being developed for the treatment of AUD. By leveraging its expertise and research capabilities, Adial Pharmaceuticals aims to address the unmet medical needs in the addiction treatment space. With an emphasis on improving patient outcomes and overall quality of life, Adial Pharmaceuticals strives to bring effective and transformative therapies to the market.

What is the P/E ratio of Adial Pharmaceuticals 2024?

The Adial Pharmaceuticals P/E ratio is -0.39.

What is the P/S ratio of Adial Pharmaceuticals 2024?

The Adial Pharmaceuticals P/S ratio is 0.

What is the AlleAktien quality score of Adial Pharmaceuticals?

The AlleAktien quality score for Adial Pharmaceuticals is 1/10.

What is the revenue of Adial Pharmaceuticals 2024?

The revenue cannot currently be calculated for Adial Pharmaceuticals.

How high is the profit of Adial Pharmaceuticals 2024?

The expected Adial Pharmaceuticals profit is -3.53 M USD.

What is the business model of Adial Pharmaceuticals

Adial Pharmaceuticals Inc is a leading biotechnology company that develops innovative drugs for the treatment of alcoholism and other diseases. The company focuses on researching, developing, and marketing novel therapies that target the causes of alcoholism. The business operations of Adial Pharmaceuticals Inc are divided into three main divisions: research and development, sales and marketing, and licensing and partnerships. The company's focus is on developing and marketing medications tailored to individual needs. In the research and development segment, the company utilizes its expertise to identify novel therapies that aim to reduce the effects of alcoholism. The company has a pipeline of candidate drugs that are designed to modulate the brain's reward system and reduce alcohol consumption. Research and development activities focusing on alcoholism and other neuropsychiatric disorders are conducted by the company's research and development departments. In the sales and marketing segment, Adial Pharmaceuticals Inc has an experienced team that works closely with physicians and healthcare facilities to raise awareness of its products. The company relies on targeted marketing and advertising efforts to ensure that its products are known and specifically prescribed by medical professionals. In the licensing and partnership sector, Adial Pharmaceuticals Inc pursues a proactive strategy to bring its products to markets worldwide. The company has formed partnerships with reputable pharmaceutical companies to accelerate the distribution of its products in global markets. The company focuses on strengthening its market position by entering into informed partnerships and licensing agreements to expand the reach of its products. The portfolio of Adial Pharmaceuticals Inc includes various products that are used in a comprehensive alcohol therapy. The Nalmefene hydrochloride tablet system for adults with alcohol dependence is the company's first drug approved in Europe. The company has also advanced the development of AD04, a drug for the treatment of alcohol dependence currently in phase III clinical trials. In summary, Adial Pharmaceuticals Inc's mission is to develop innovative therapies for alcoholism and other neuropsychiatric disorders. The company relies on research and development, sales and marketing, and licensing and partnerships to bring its products to markets worldwide. Adial Pharmaceuticals Inc aims to raise awareness of its products to ensure the spread of its products and the success of its mission.

What is the Adial Pharmaceuticals dividend?

Adial Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Adial Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Adial Pharmaceuticals or the company does not pay out a dividend.

What is the Adial Pharmaceuticals ISIN?

The ISIN of Adial Pharmaceuticals is US00688A1060.

What is the Adial Pharmaceuticals WKN?

The WKN of Adial Pharmaceuticals is A2N38J.

What is the Adial Pharmaceuticals ticker?

The ticker of Adial Pharmaceuticals is ADIL.

How much dividend does Adial Pharmaceuticals pay?

Over the past 12 months, Adial Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adial Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adial Pharmaceuticals?

The current dividend yield of Adial Pharmaceuticals is .

When does Adial Pharmaceuticals pay dividends?

Adial Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adial Pharmaceuticals?

Adial Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adial Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adial Pharmaceuticals located?

Adial Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adial Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adial Pharmaceuticals from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Adial Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Adial Pharmaceuticals in the year 2023?

In the year 2023, Adial Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adial Pharmaceuticals pay out the dividend?

The dividends of Adial Pharmaceuticals are distributed in USD.

All fundamentals about Adial Pharmaceuticals

Our stock analysis for Adial Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adial Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.